Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
0.5394
+0.0186 (3.57%)
At close: Sep 2, 2026, 4:00 PM EDT
0.5400
+0.0006 (0.11%)
After-hours: Sep 2, 2026, 4:35 PM EDT
Evogene Employees
Evogene had 38 employees as of June 30, 2026. The number of employees decreased by 14 or -26.92% since the number was reported on December 31, 2025.
Employees
38
Change
-14
Growth
-26.92%
Revenue / Employee
$43,605
Profits / Employee
-$238,763
Market Cap
7.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 38 | -14 | -26.92% | 38 | 0 |
| Dec 31, 2025 | 52 | -65 | -55.56% | 52 | 0 |
| Dec 31, 2024 | 117 | -25 | -17.61% | 117 | 0 |
| Dec 31, 2023 | 142 | 5 | 3.65% | 142 | 0 |
| Dec 31, 2022 | 137 | -4 | -2.84% | 137 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| Bolt Biotherapeutics | 23 |
| AIM ImmunoTech | 21 |
| Soligenix | 14 |
| Ensysce Biosciences | 10 |
| Ernexa Therapeutics | 7 |
| Alzamend Neuro | 6 |
| Can-Fite BioPharma | 5 |
EVGN News
- 2 days ago - Evogene responds to latest communication from L.I.A. Pure Capital, Invest-Pro - TheFly
- 2 days ago - Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward - PRNewsWire
- 7 days ago - EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026 - Business Wire
- 8 days ago - Evogene (EVGN) Q2 2026 Earnings Call Transcript - The Motley Fool
- 8 days ago - Evogene’s director nominees recommended by ISS and Glass Lewis - TheFly
- 8 days ago - Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees - PRNewsWire
- 15 days ago - Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35% - AlphaStreet
- 15 days ago - Evogene Q2 Loss Narrows As AI Transformation Drives Strategic Progress - Nasdaq